Vaccine | Trade Name (Manufacturer) | Age | Dose | Route | Sched-Ule | Booster |
Cholera CVD 103-HgR vaccine | Vaxchora (PaxVax) | 18–64 y | 100 mL (reconstituted) | Oral | 1 dose 1 | Undetermined 2 |
Hepatitis A vaccine, inactivated | Havrix (GlaxoSmithKline) | 1–18 y | 0.5 mL (720 ELISA units) | IM | 0 and 6–12 mo | None |
≥19 y | 1 mL (1,440 ELISA units) | IM | 0 and 6–12 mo | None | ||
Hepatitis A vaccine, inactivated | Vaqta (Merck & Co., Inc.) | 1–18 y | 0.5 mL (25 U) | IM | 0 and 6–18 mo | None |
≥19 y | 1 mL (50 U) | IM | 0 and 6–18 mo | None | ||
Hepatitis B vaccine, recombinant with novel adjuvant (1018) | Heplisav-B (Dynavax Technologies Corp.) | >18 | 0.5 mL (20 µg HBsAg and 3,000 µg of 1018) | IM | 0, 1 mo | None |
Hepatitis B vaccine, recombinant 3 | Engerix-B (GlaxoSmithKline) | 0–19 y | 0.5 mL (10 μg HBsAg) | IM | 0, 1, 6 mo | None |
0–10 y (accelerated) | 0.5 mL (10 μg HBsAg) | IM | 0, 1, 2 mo | 12 mo | ||
11–19 y (accelerated) | 1 mL (20 μg HBsAg) | IM | 0, 1, 2 mo | 12 mo | ||
≥20 y (primary) | 1 mL (20 μg HBsAg) | IM | 0, 1, 6 mo | None | ||
≥20 y (accelerated) | 1 mL (20 μg HBsAg) | IM | 0, 1, 2 mo | 12 mo | ||
Hepatitis B vaccine, recombinant 3 | Recombivax HB (Merck & Co., Inc.) | 0–19 y (primary) | 0.5 mL (5 μg HBsAg) | IM | 0, 1, 6 mo | None |
11–15 y (adolescent accelerated) | 1 mL (10 μg HBsAg) | IM | 0, 4–6 mo | None | ||
≥20 y (primary) | 1 mL (10 μg HBsAg) | IM | 0, 1, 6 mo | None | ||
Combined hepatitis A and hepatitis B vaccine | Twinrix (GlaxoSmithKline) | ≥18 y (primary) | 1 mL (720 ELU HAV + 20 μg HBsAg) | IM | 0, 1, 6 mo | None |
≥18 y (accelerated) | 1 mL (720 ELU HAV + 20 μg HBsAg) | IM | 0, 7, and 21–30 d | 12 mo | ||
Japanese encephalitis vaccine, inactivated | Ixiaro (Valneva) | 2 mo-2 y | 0.25 mL | IM | 0, 28 d | ≥1 year after primary series 4 |
3-17 y | 0.5 mL | IM | 0, 28 d | ≥1 year after primary series 4 | ||
18-65 y | 0.5 mL | IM | 0, 7-28 d | ≥1 year after primary series 4 | ||
>65 y | 0.5 mL | IM | 0, 28 d | ≥1 year after primary series 4 | ||
Meningococcal (serogroups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D) 5 | Menactra (Sanofi Pasteur) | 9–23 mo | 0.5 mL | IM | 0, 3 mo | If at continued risk 7 |
≥ 2 y | 0.5 mL | IM | 1 dose 6 | |||
Meningococcal (serogroups A, C, W, and Y) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) 5 | Menveo (GSK) | 2 mo | 0.5 mL | IM | 0, 2, 4, 10 mo | If at continued risk 7 |
7–23 mo | 0.5 mL | IM | 0,3 mo (2nd dose administered in 2nd year of life) | |||
≥ 2 y | 0.5 mL | IM | 1 dose 6 | |||
Polio vaccine, inactivated | Ipol (Sanofi Pasteur) | ≥18 y | 0.5 mL | SC or IM | 1 dose if patient has completed a pediatric series | Repeat boosters may be needed for long-term travelers to polio-affected countries; see Chapter 4, Polio |
Rabies vaccine (human diploid cell) | Imovax (Sanofi Pasteur) | Any | 1 mL | IM | Preexposure series: days 0, 7, and 21 or 28 d | None; see Chapter 4, Rabies for postexposure immunization |
Rabies vaccine (purified chick embryo cell) | RabAvert (Novartis) | Any | 1 mL | IM | Preexposure series: days 0, 7, and 21 or 28 d | None; see Chapter 4, Rabies for postexposure immunization |
Typhoid vaccine (oral, live, attenuated) | Vivotif (PaxVax) | ≥6 y | 1 capsule 8 | Oral | 0, 2, 4, 6 d | Repeat primary series after 5 y |
Typhoid vaccine (Vi capsular polysaccharide) | Typhim Vi (Sanofi Pasteur) | ≥2 y | 0.5 mL | IM | 1 dose | 2 y |
17D yellow fever vaccine | YF-Vax (Sanofi Pasteur) | ≥9 mo 9 | 0.5 mL 10 | SC | 1 dose | Not recommended for most 11 |
Abbreviations: ACIP, Advisory Committee on Immunization Practices; ELU, ELISA units of inactivated HAV; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; IM, intramuscular; U, units HAV antigen; SC, subcutaneous. | ||||||
1 Must be administered in a health care setting. | ||||||
2 In a clinical trial, vaccine efficacy was 90% at 10 days postvaccination and declined to 80% at 3 months postvaccination in prevention of severe diarrhea after oral cholera challenge. Long-term immunogenicity is unknown. Clinicians advising travelers who are at continued or repeated risk over an extended period may consider revaccination, although the appropriate interval and efficacy are unknown. | ||||||
3 Consult the prescribing information for differences in dosing for hemodialysis and other immunocompromised patients. | ||||||
4 If potential for Japanese encephalitis virus exposure continues. | ||||||
5 If an infant is receiving the vaccine before travel, 2 doses may be administered as early as 8 weeks apart. | ||||||
6 For people with HIV, anatomic or functional asplenia, and people with persistent complement component deficiencies (C3, C5-9, properdin, factor D, and factor H or people taking eculizumab [Soliris]) should receive a 2-dose primary series 8–12 weeks apart. | ||||||
7 Revaccination with meningococcal conjugate vaccine (MenACWY-D or MenACWY-CRM) is recommended after 3 years for children who received their last dose at <7 years of age. Revaccination with meningococcal conjugate vaccine is recommended after 5 years for people who received their last dose at ≥7 years of age, and every 5 years thereafter for people who are at continued risk. | ||||||
8 Must be kept refrigerated at 35.6°F–46.4°F (2°C–8°C); administer with cool liquid no warmer than 98.6°F (37°C). | ||||||
9 Ages 6–8 months and ≥60 years are precautions and age <6 months is a contraindication to the use of yellow fever vaccine. | ||||||
10 YF-Vax is available in single-dose and multiple-dose (5-dose) vials. | ||||||
11 For full details regarding revaccination, see “Vaccine Administration” in Chapter 4, Yellow Fever. | ||||||
There's more to see -- the rest of this topic is available only to subscribers.